Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: TOVX )

5.900 +1.200 (+25.53%)
Official Closing Price Updated: 8:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,144,131
Open 6.180
Bid (Size) 5.560 (8)
Ask (Size) 5.650 (24)
Prev. Close 4.700
Today's Range 4.950 - 7.150
52wk Range 2.665 - 17.11
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Theriva Biologics Stock?
Theriva Biologics shares are trading higher Friday on continued momentum following a series of catalysts this week. Here's a look at the details: 
Via Benzinga
Nasdaq Jumps Over 100 Points; Dell Posts Upbeat Results
Via Benzinga

Performance

YTD
-46.49%
-46.49%
1 Month
+8.16%
+8.16%
3 Month
-10.27%
-10.27%
6 Month
-51.44%
-51.44%
1 Year
-54.17%
-54.17%

More News

Read More
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma
Via News Direct
Exposures Product Safety
Peering Into Theriva Biologics's Recent Short Interest
Via Benzinga
What's Going On With Theriva Biologics (TOVX) Stock?
Via Benzinga
Preview: Theriva Biologics's Earnings
Via Benzinga
Nasdaq Surges 150 Points; Sonder Holdings Shares Surge
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Dow Jumps Over 100 Points; Estee Lauder Shares Edge Lower After Q4 Results
Via Benzinga
Topics Stocks
Exposures US Equities
TOVX Stock Earnings: Theriva Biologics Beats EPS for Q2 2024
Via InvestorPlace
Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers
Via News Direct
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer
Via News Direct
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
TOVX Stock Earnings: Theriva Biologics Beats EPS for Q1 2024
Via InvestorPlace
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers
Via News Direct
Earnings Scheduled For March 25, 2024
Via Benzinga
How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need
Via News Direct
Topics Death
Exposures Death
Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology
Via News Direct
For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers
Via News Direct
Topics Death
Exposures Death
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.